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Polymyxin B dose fractionation
This study was conducted at Midwestern University, Downers Grove, IL. The study methods were reviewed and 1 0 1 approved by the Midwestern University Institutional Animal Care and Use Committee (IACUC; protocol 2677). All 1 0 2 animals were cared for and handled in concordance with animal care and use standards and ethical principles. ketamine (100 mg/kg) and xylazine (10 mg/kg) anesthesia for surgical procedure and were allowed 24-hour 1 0 8 recovery periods prior to initiation of the study protocol (i.e. drug dosing or blood sampling). When not in use, 1 0 9 catheters were locked with heparin solution (100 IU/mL). Blood samples (0.125 mL aliquots) were obtained after 1 1 0 the first dose (day 1) with a staggered sampling design. A maximum of 16 samples per animal were obtained during 1 1 1 a 4-day period (pre-euthanasia) and no more than 8 samples were drawn in a single day. As an example, for QD and 1 1 2 control groups blood samples were drawn at 5, 20, 60, 120, 180, 240, 360, and 480 minutes after the first dose on 1 1 3 day 1. Eight blood samples total were then obtained on days 2 and 3. A terminal sample was also drawn under 1 1 4 terminal anesthesia. Blood sampling schemes for BID and TID groups follow the same protocol (i.e. maximum 1 1 5 number of samples and volume per animal) while the sampling times were adjusted accordingly based on the dosing 1 1 6 intervals. Each sample was replaced with equal volume of NS to maintain euvolemia. Blood samples were 1 1 7 immediately transferred to a disodium EDTA (Sigma-Aldrich Chemical Company, Milwaukee, WI, USA) treated 1 1 8 microcentrifuge tube and centrifuged at 600 xg for 10 minutes. Plasma supernatant was collected and stored at - 1 1 9 80°C for batch sample analysis. Animals were placed in metabolic cages for urine collection as previously 1 2 0 described (34, 35). In brief, discrete entry times were recorded for initial transfer of animals to the metabolic cages (catalogue number 650-0350; Nalgene, Rochester, NY) on day -1 (baseline), and urine collections and volume 1 2 2 measurements followed the 24-hour period on days 2, 3 and 4. All urine samples were collected in laboratory-1 2 3 controlled ambient conditions, and urinary biomarkers were stable throughout as previously described (35). Urine samples were centrifuged at 500 xg at 4°C for 10 minutes, and supernatant was stored at -80°C for batch analysis. 
Determination of PB and creatinine concentrations in plasma
For quantification of plasma PB concentration, 40 µL plasma sample was combined with 4 µL of internal standard 1 2 8 of colistin sulfate at a concentration of 0.1 mg/mL. Protein precipitation was then performed with 456 µL of 1 2 9 methanol containing 0.1% formic acid. Following centrifugation for 10 minutes at 16,000 xg (Eppendorf model: creatinine-d3 and creatinine, respectively. After adjusting for endogenous creatinine in pooled blank plasma and 1/x 1 3 7 weighting, the linear range for creatinine assay was between 0.3 and 40 mg/dL (R 2 =0.999). The coefficient of 1 3 8 variation (CV%) values for PB1 and creatinine assays were below 10% for intra-and inter-day measures. All Kidney tissues were harvested following euthanasia. Each animal's kidneys were removed and briefly washed in system was employed to grade pathological lesions as previously described (31, 36, 37) . Briefly, a scale of 0 score for an individual animal was calculated based on the highest score from the anatomical structural segment. To construct the base PK models and generate exposure estimates for each individual animal, the Nonparametric Adaptive Grid (NPAG) algorithm (38, 39) within the Pmetrics (Version 1.5.2) package (39) for R (6) was utilized. Multiple models were built and assessed. A three-compartmental structural model of PB disposition accounting for 1 6 0 absorption constant (K a ) from injection site to the central compartment (V C ) was fitted to all PK data. The PK 1 6 1 model was parameterized with K a , V C , intercompartmental transfer rates (K 23 , K 32 ) between central and peripheral 1 6 2 (V P ) compartments, and total elimination rate constant (K e ). Assay error was included in the model using a Analysis of variance (ANOVA) with Geisser and Greenhouse epsilon hat correction method accounting for subjects, statistical analyses of urinary biomarkers, plasma creatinine, and PK indices between study groups using GraphPad C MAX for QD, BID, and TID groups were 10.7 (0.80), 9.7 (0.47), and 6.7 (0.49) mg/L, respectively and mean C MIN groups showed significantly higher C MAX during the first 24 hours (p=0.0083 and p=0.049, respectively). The QD group exhibited the highest C MAX on days 2 and 3 (p=0.0025 and p=0.0017, respectively). On days 2 and 3, the Mean KIM-1 changes did not differ on days 2 and 3 between QD and BID groups. Similar trends and significant 2 2 6 treatment and time effects were also observed for OPN (p=0.029), IP-10 (p=0.046), and TIMP-1 (p<0.0001) but no 2 2 7 significant effects were observed with CLN (p=0.093) ( Fig. 6 ). Histopathological scorings are summarized in Table 3 and graphically displayed in Supplemental Figure S1 . Representative histopathology images are provided in supplemental materials ( Figures S2, S3 , S4 and S5). aliquots resulted in the most kidney injury as measured by the urinary biomarkers: KIM-1, OPN, IP-10, and TIMP-1. derived a best-fit PK model for PB in rats using rich PK data. Utilizing the best-fit model, we found that the PB provided rich PK data to confirm the exposure status across experimental groups and employed highly sensitive and 2 7 2 specific urinary biomarkers for early detection of AKI in addition to plasma creatinine (46). The level of injury was 2 7 3 further confirmed by histopathological examination. We acknowledge several limitations to our study. First, our study was limited to 72-hour dosing compared to the To date, this is the first study that employed a rat model with a rich PK sampling design with dose fractionated 2 8 6 systemic PB that also allowed PK estimates at an individual level. We also demonstrated that TID dosing of PB Twice-Daily Dosing Regimen. Antimicrob Agents Chemother 62, (2018). Chemother 60, 5742-51 (2016). for Administration to Critically Ill Patients. Ann Pharmacother 50, 790-2 (2016). in preclinical biomarker qualification studies. Nat Biotechnol 28, 478-85 (2010). 
